Down Day For Drugmakers… And Intel Jumps On Deal Rumors 1/17/25
CNBC's "Fast Money"
Intro
This chapter explores the recent challenges faced by Novo Nordisk as its shares reach an 18-month low amid new drug price negotiations. It examines the broader implications for the obesity drug market and potential future strategies in response to evolving pricing pressures and competition.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
